Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor
Authors:
- 1 January 2003
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 63 (1) , 211-223
Abstract
The purposes of the present studies were to examine the androgen receptor (AR) binding ability and in vitro functional activity of multiple series of nonsteroidal compounds derived from known antiandrogen pharmacophores and to investigate the structure-activity relationships (SARs) of these nonsteroidal compounds. The AR binding properties of sixty-five nonsteroidal compounds were assessed by a radioligand competitive binding assay with the use of cytosolic AR prepared from rat prostates. The AR agonist and antagonist activities of high-affinity ligands were determined by the ability of the ligand to regulate AR-mediated transcriptional activation in cultured CV-1 cells, using a cotransfection assay. Nonsteroidal compounds with diverse structural features demonstrated a wide range of binding affinity for the AR. Ten compounds, mainly from the bicalutamide-related series, showed a binding affinity superior to the structural pharmacophore from which they were derived. Several SARs regarding nonsteroidal AR binding were revealed from the binding data, including stereoisomeric conformation, steric effect, and electronic effect. The functional activity of high-affinity ligands ranged from antagonist to full agonist for the AR. Several structural features were found to be determinative of agonist and antagonist activities. The nonsteroidal AR agonists identified from the present studies provided a pool of candidates for further development of selective androgen receptor modulators (SARMs) for androgen therapy. Also, these studies uncovered or confirmed numerous important SARs governing AR binding and functional properties by nonsteroidal molecules, which would be valuable in the future structural optimization of SARMs.Keywords
This publication has 37 references indexed in Scilit:
- Selective estrogen receptor modulatorsCurrent Opinion in Rheumatology, 1999
- Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate and DihydrotestosteroneMolecular Endocrinology, 1999
- Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)Journal of Medicinal Chemistry, 1999
- Discovery of Nonsteroidal AndrogensBiochemical and Biophysical Research Communications, 1998
- Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited TrypsinizationJournal of Biological Chemistry, 1995
- Effects of Androgens and Antiandrogens on the Conformation of the Androgen ReceptorAnnals of the New York Academy of Sciences, 1995
- Mechanism of antiandrogen action: Conformational changes of the receptorMolecular and Cellular Endocrinology, 1994
- Agonists, but not antagonists, alter the conformation of the hormone- binding domain of androgen receptorEndocrinology, 1994
- Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilidesJournal of Medicinal Chemistry, 1988
- Pharmacology and clinical use of antiandrogens: A short reviewIrish Journal of Medical Science (1971 -), 1982